EuniceWangMD

Hematologic Oncology

Chief, Clinical Leukemia Service and Professor of Oncology, Dept Medicine, Roswell Park Cancer Institute; Associate Professor, Dept Medicine, University of Buffalo (UB) SUNY School of Medicine; and Associate Director, UB/RPCI Hematology-Oncology Fellowship

Join to view full profile

Dr. Wang is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Wang's full profile

Already have an account?

Office
Elm and Carlton St
Buffalo, NY 14263
Phone+1 716-845-2300

Fax+1 716-845-8741

Summary

I am a hematologist-oncologist and physician scientist whose clinical practice focuses on the treatment of patients with acute and chronic leukemia, myeloid disorders, and benign hematological conditions.

Education & Training

Memorial Sloan Kettering Cancer Center1999 - 2003
Yale-New Haven Medical CenterResidency, Internal Medicine, 1997 - 1999
Keck School of Medicine of the University of Southern CaliforniaClass of 1996
Harvard UniversityBA, Biology, Cum Laude, 1987 - 1991

Certifications & Licensure

NY State Medical License 1999 - 2025

Clinical Trials

Feasibility and Outcomes of Allogeneic HCT Compared to Chemotherapy in Older AML Patients Start of enrollment: 2013 Jul 19
Completed
Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia Start of enrollment: 2014 May 19
Active, not recruiting
Phase 3
Study of Combination Ruxolitinib and Decitabine Treatment for Accelerated Phase MPN or Post-MPN AML Start of enrollment: 2014 Feb 01
Completed
Phase 1, Phase 2
SL-401 in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm or Acute Myeloid Leukemia Start of enrollment: 2014 Sep 01
Completed
Phase 1, Phase 2
Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia Start of enrollment: 2015 Jun 30
Active, not recruiting
Phase 2
SL-401 as Consolidation Therapy in Patients With Adverse Risk Acute Myeloid Leukemia in First Complete Remission Start of enrollment: 2015 Feb 01
Terminated
Phase 1, Phase 2
A Safety and Tolerability Study of Crenolanib in Combination With Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia Patients With FLT3 Mutations Start of enrollment: 2015 Jan 01
Completed
Phase 2
Phase 1/2 Study of the ERK1/2 Inhibitor BVD-523 in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndromes Start of enrollment: 2014 Nov 01
Completed
Phase 1, Phase 2
Open-label Study of IMGN779 in Adult Patients With Relapsed/Refractory CD33-positive Acute Myeloid Leukemia Start of enrollment: 2016 Mar 01
Completed
Phase 1
A Safety Study of Human Cord Blood Derived, Culture Expanded Natural Killer Cell (PNK-007) Infusion With Subcutaneous Recombinant Human IL-2 (rhIL-2) in Adults With Relapsed and/or Refractory Acute Myeloid Leukemia (AML) Start of enrollment: 2016 Jul 11
Terminated
Phase 1
Vadastuximab Talirine (SGN-CD33A; 33A) Combined With Azacitidine or Decitabine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Start of enrollment: 2016 May 01
Terminated
Phase 3
Inotuzumab Ozogamicin and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia Start of enrollment: 2021 Jan 21
Withdrawn
Phase 1, Phase 2
CPI-613 and Hydroxychloroquine for Patients With High Risk Myelodysplastic Syndrome Start of enrollment: 2021 May 01
Withdrawn
Phase 1, Phase 2
Study of Alvocidib in Patients With Relapsed/Refractory AML Following Treatment With Venetoclax Combination Therapy Start of enrollment: 2020 Jan 15
Terminated
Phase 2
Talazoparib and Gemtuzumab Ozogamicin for the Treatment of CD33 Positive Relapsed or Refractory Acute Myeloid Leukemia Start of enrollment: 2020 Oct 23
Active, not recruiting
Phase 1
Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies Start of enrollment: 2018 Mar 19
Recruiting
Phase 1, Phase 2
Roles: Principal Investigator, Contact
Study of Crenolanib vs Midostaurin Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed FLT3 Mutated AML Start of enrollment: 2018 Aug 15
Recruiting
Phase 3
Roles: Contact
Tagraxofusp (SL-401) in Patients With CMML or MF Start of enrollment: 2014 Dec 01
Completed
Phase 2
Roles: Principal Investigator, Contact
Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN Start of enrollment: 2018 Jan 02
Active, not recruiting
Phase 1, Phase 2
Roles: Principal Investigator, Contact
A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia Start of enrollment: 2018 Oct 04
Active, not recruiting
Phase 3
Roles: Principal Investigator
A Study of GDX012 in Adults With Relapsed or Refractory Acute Myeloid Leukemia Start of enrollment: 2023 Jul 11
Recruiting
Phase 1, Phase 2
Roles: Principal Investigator
A Study of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher Risk Myelodysplastic Syndromes Start of enrollment: 2024 Jan 11
Recruiting
Phase 1
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

38 citations
A Phase Ib Study of Onvansertib, a Novel Oral PLK1 Inhibitor, in Combination Therapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia
Amer M. Zeidan, Maya Ridinger, Tara L. Lin, Pamela S. Becker, Gary J. Schiller
Clinical Cancer Research. 2020-09-30
280 citations
Acute myeloid leukemia, version 3.2019
Martin S. Tallman, Eunice S. Wang, Jessica K. Altman, Frederick R. Appelbaum, Vijaya Raj Bhatt
Journal of the National Comprehensive Cancer Network. 2019-01-01
32 citations
Is obesity a prognostic factor for acute myeloid leukemia outcome
Hun Ju Lee, Andrea S. Licht, Andrew Hyland, Laurie A. Ford, Sheila N.J. Sait
Annals of Hematology. 2012-03-01

Journal Articles

NF1 Mutations Are Recurrent in Adult Acute Myeloid Leukemia and Confer Poor Outcome
Eunice S Wang, Bayard L Powell, Richard M Stone, John C Byrd, Clara D Bloomfield, Alice Mims, Andrew J Carroll, Jonathan E Kolitz, James S Blachly, Nature

Abstracts/Posters

Mitophagy Plays a Key Role in the Anti-Leukemic Activity of Autophagy Inhibitors Under Hypoxia in Acute Myeloid Leukemia
Eunice S. Wang, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Safety, Efficacy and Biomarker Analysis of a Phase 1b/2 Study of Onvansertib (ONV), a Polo-like Kinase 1 (PLK1) Inhibitor, in Combination with Low-Dose Cytarabine (LDA...
Eunice S. Wang, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
The 2017 European Leukemianet Genetic Risk Classification Performs Poorly in Older Patients with Acute Myeloid Leukemia (AML) and Should be Refined to Identify Patient...
Eunice S. Wang, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Younger Patients with Newly Diagnosed FLT3-Mutant AML Treated with Crenolanib Plus Chemotherapy Achieve Adequate Free Crenolanib Levels and Durable Remissions
Eunice S. Wang, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Benefits of a Pharmacist Led Oral Chemotherapy Monitoring Program for Patients with Chronic Myeloid Malignancies: A Patient Reported Outcome (PRO) Study
Eunice S. Wang, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
A Phase 1b Study of Glasdegib in Combination with Azacitidine in Patients with Untreated Higher-Risk Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Mye...
Eunice S. Wang, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Outcomes of AML Patients Treated with Gemtuzumab-Ozogamicin Based Therapies: A Cue to Optimal Chemotherapy Backbone
Eunice S. Wang, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Results of a Clinical Trial of H3B-8800, a Splicing Modulator, in Patients with Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic...
Eunice S. Wang, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Cladribine, Cytarabine, Granulocyte Colony Stimulating Factor ± Mitoxantrone (CLAG ± M) Is Highly Effective Therapy for Secondary and Relapsed/Refractory Acute Myeloid...
Eunice S. Wang, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Addition of the PARP Inhibitor, Talazoparib, to Gemtuzumab Ozogamicin Significantly Enhances Anti-Leukemic Activity in Human CD33+ Acute Myeloid Leukemia
Eunice S. Wang, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
A Phase I Study of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate, in Patients with Relapsed/Refractory Acute Myeloid Leukemia, Blastic Plasmacytoid Dendriti...
Eunice S. Wang, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Olutasidenib (FT-2102), an IDH1m Inhibitor As a Single Agent or in Combination with Azacitidine, Induces Deep Clinical Responses with Mutation Clearance in Patients wi...
Eunice S. Wang, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Outcomes of Venetoclax-Based Regimens Compared with Hypomethylating Agents (HMA) Alone or 7+3 in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia (AML): A ...
Eunice S. Wang, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Clinical Profile of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) or Blastic ...
Eunice S. Wang, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
A Phase 1b/2 Study of the CD123-Targeting Antibody-Drug Conjugate IMGN632 As Monotherapy or in Combination with Venetoclax and/or Azacitidine for Patients with CD123-P...
Eunice S. Wang, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Genetic Alterations at Diagnosis Predict Outcome of AML Patients Age 60 or Older Undergoing Allogeneic Transplantation in First RemissionClinically Relevant Abstract
Eunice S. Wang, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Olutasidenib (FT-2102) Induces Rapid Remissions in Patients with IDH1-Mutant Myelodysplastic Syndrome: Results of Phase 1/2 Single Agent Treatment and Combination with...
Eunice S. Wang, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Feasibility of Flow Cytometric Identification and Isolation of Pre-Platelets to Understand Its Function and Role in Cancer Metastasis
Eunice S. Wang, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Results from a Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Intermediate, or High Risk, Relapsed/Refractory Myelofibrosis
Eunice S. Wang, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Quantification of Humoral Immune Response to Influenza Vaccination in MDS
Eunice S. Wang, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all

Lectures

Tolerability and Efficacy of Crenolanib and Cytarabine/Anthracycline Chemotherapy in Older Patients (Aged 61 to 75) with Newly Diagnosed FLT3-Mutated Acute Myeloid Leu...
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
AML: Expert Guidance on Current Standards and New Directions in Patient Care
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Prognostic and Biologic Significance of Transfer RNA-Derived Small RNAs (tsRNAs) Expression in Younger Adult Patients (Pts) with Cytogenetically Normal Acute Myeloid L...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Limitations to Receiving Allogeneic Hematopoietic Cell Transplantation for Treatment of Acute Myeloid Leukemia: A Large Multi-Center Prospective Longitudinal Observati...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Phase 1 Studies Assessing the Safety and Clinical Activity of Multiple Doses of a NKG2D-Based CAR-T Therapy, Cyad-01, in Acute Myeloid Leukemia
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Zella 201: A Biomarker-Guided Phase II Study of Alvocidib Followed By Cytarabine and Mitoxantrone in MCL-1 Dependent Relapsed/Refractory Acute Myeloid Leukemia (AML)
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Addition of Crenolanib to Induction Chemotherapy Overcomes the Poor Prognostic Impact of Co- Occurring Driver Mutations in Patients with Newly Diagnosed FLT3-Mutated AML
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
A Phase I, First-in-Human Study Evaluating the Safety and Preliminary Antileukemia Activity of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate, in Patients wi...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
FT-2102, an IDH1m Inhibitor, in Combination with Azacitidine in Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Ayndrome (MDS): Results from a Phase 1 Study
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Clinical Outcomes for Patients with Myeloid Malignancies Harboring IDH1/2mutations after Intensive Chemotherapy
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
A Precision Medicine Heirarchical Classification Developed Using Variant Allele Frequency (VAF) for Treatment of Older Patients (Pts) with Acute Myeloid Leukemia (AML)...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Maturing Clinical Profile of IMGN779, a Next-Generation CD33-Targeting Antibody-Drug Conjugate, in Patients with Relapsed or Refractory Acute Myeloid Leukemia
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Moving Toward Precision Therapy for Patients with AML: Clinical Challenges and Future Directions
60th American Society of Hematology Annual Meeting - 11/30/2018
Join now to see all

Press Mentions

Study Highlights Promising New Treatment Option for Patients with Treatment-Resistant Acute Myeloid LeukemiaOctober 1st, 2024
Biomarker Uncovered by Roswell Park Team Identifies NET Patients Likely to Have Blood Side Effects from PRRTJune 9th, 2021
Roswell Park Researchers Gear up for ASCO 2021 Annual MeetingJune 3rd, 2021
Join now to see all

Committees

Member, Scientific Review Committee 2009 - Present
Member, Fellowship Program Committee 2007 - Present

Professional Memberships

American Society of Hematology - ASH
Member
American Society of Clinical Oncology - ASCO
Member
American Association for Cancer Research - AACR
Member

External Links

roswellpark.orghttps://www.roswellpark.org/eunice-wang
roswellpark.eduhttps://www.roswellpark.edu/eunice-wang
buffalo.eduhttps://medicine.buffalo.edu/content/medicine/faculty/profile.html?ubit=ewang3